Jason Tardio - Jul 1, 2021 Form 4 Insider Report for Ovid Therapeutics Inc. (OVID)

Role
Chief Commercial Officer
Signature
/s/ Danielle Mann for Jason Tardio by PoA
Stock symbol
OVID
Transactions as of
Jul 1, 2021
Transactions value $
$0
Form type
4
Date filed
7/1/2021, 04:23 PM
Next filing
Feb 4, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OVID Stock Option (Right to Buy) Award $0 +50K $0.00 50K Jul 1, 2021 Common Stock 50K $3.95 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the Stock Option will vest and become exercisable on July 1, 2022 and the remaining shares will vest in 36 equal monthly installments thereafter subject to the Reporting Person's continued services through such date.